Table 2. Standard and Predictive Models of 1-, 2-, and 4-kHz PTA After Treatment.
| Model | β (95% CI) |
|---|---|
| Standard model | |
| Age (per 10 y) | 0.05 (0.08 to 2.03) |
| Baseline 1-, 2-, and 4-kHz PTA | 0.95 (0.90 to 1.01) |
| Total cumulative cisplatin dose (per 100 mg/m2 of cisplatin) | 2.92 (2.34 to 3.51) |
| Mean cochlear radiotherapy dose (per 10 Gy) | 0.92 (0.33 to 1.50) |
| Predictive model | |
| Age (per 10 y) | 1.08 (0.08 to 2.08) |
| Baseline 1-, 2-, and 4-kHz PTA | 0.95 (0.90 to 1.01) |
| Planned cisplatin regimen | |
| None | 0 [Reference] |
| Induction and high-dose | 13.57 (10.53 to 16.62) |
| Othera | 5.35 (3.14 to 7.56) |
| Primary tumor site by approximate distance to cochlea | |
| Far | 0 [Reference] |
| Mid-Far | 1.57 (0.48 to 3.62) |
| Mid-Near | 1.97 (0.15 to 3.79) |
| Close | 2.46 (–1.02 to 5.93 |
Abbreviation: PTA, pure tone average.
a
Other includes induction, low-dose, induction and low-dose, and high-dose regimens.